4D Molecular Therapeutics (FDMT) Earnings Analysis

4D Molecular Therapeutics (FDMT) next reports earnings on 2026-08-10, consensus EPS -1.04 USD. Last quarter (2026-05-07) it missed with EPS -1.01 USD vs -0.97 USD est (-4.1%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -4.12.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does FDMT next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-1.04 USD
Revenue estimate0.00B

FDMT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-1.01 USD-0.97 USD-4.1%Miss
2026-03-180.43 USD-0.53 USD+181.1%Beat
2025-11-10-1.01 USD-1.02 USD+1%Beat
2025-08-11-0.98 USD-0.88 USD-11.4%Miss
2025-02-28-0.9 USD-0.8 USD-12.5%Miss

Beat rate: 2/5 (40%) over reported quarters with consensus data.

FDMT valuation and analyst view

Trailing P/E-4.12
Trailing EPS-2.36389 USD
Price / book1.65
Dividend yield0.00%
Market cap0.58B
Analyst consensusBuy (10 buy / 3 hold / 1 sell)
Avg price target33 USD

Related research pages

Frequently asked questions

When is 4D Molecular Therapeutics (FDMT)'s next earnings date?

4D Molecular Therapeutics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -1.04 USD and revenue estimate of 0.00B.

Did FDMT beat earnings last quarter?

In its 2026-05-07 report, FDMT posted EPS of -1.01 USD versus a -0.97 USD estimate — a miss of 4.1%.

What is FDMT's earnings track record?

Over the last 5 reported quarters with consensus data, FDMT beat estimates 2 times (40%).

What is FDMT's current P/E ratio and EPS?

FDMT trades at a trailing P/E of -4.12 on trailing EPS of -2.363887146834332 USD.

What do analysts rate FDMT?

Analyst consensus is "Buy" across 14 ratings (0 strong buy, 10 buy, 3 hold, 1 sell, 0 strong sell). Average 12-month price target: 33 USD.